Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an announcement.
China Resources Pharmaceutical Group has completed the regulatory registrations and industry association filings required to establish a new private investment fund in mainland China, securing a filing record from the Asset Management Association of China. The fund will be managed by Shenzhen CR Capital, an experienced AMAC-licensed private fund manager with a track record across pharmaceuticals, healthcare and other high-tech sectors, and CR Pharm (Shantou), a wholly owned subsidiary of the Group, will serve as a general and executive partner actively involved in daily management, project sourcing and post-investment cooperation. The fund is expected to invest in synthetic biology, innovative drugs and biotechnology and, although accounted for as an equity investment, is intended to connect the Group with key companies, products, policy support and industrial resources in Hohhot’s emerging synthetic biology ecosystem, supporting the Group’s strategy to build a synthetic biology industrialization platform and deepen its presence in cutting-edge life science technologies.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical conglomerate whose businesses span pharmaceuticals and healthcare, with a focus on drug manufacturing, distribution and related healthcare investments in mainland China. Through its subsidiaries, the Group also participates in sector-focused investment funds to support innovation and industrial development in areas such as synthetic biology, innovative drugs and biotechnology.
Average Trading Volume: 13,593,600
Technical Sentiment Signal: Sell
Current Market Cap: HK$28.71B
For an in-depth examination of 3320 stock, go to TipRanks’ Overview page.